The glucagon receptor activation component sets Retatrutide apart from other peptide therapies
R NAT2 is the more clinically relevant because it metabolizes the majority of amine drugs (isoniazid, hydralazine, procainamide, sulfonamides, caffeine)
Studies such as the LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown reductions in major adverse cardiovascular events, including heart attack and stroke, in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk
Researchers are particularly interested in its potential to aid muscle hypertrophy, speed up recovery time, and improve fat metabolism
Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1renal axis in man
A deficiency in Vitamin B6 can lead to excessive sebum production, potentially causing skin problems